Investigational Site Number : 8260002

London, Harrow NW10 7NS

1 studies enrolling now · 1 studies all time

What they study most

Sickle Cell Disease

Studies at this site

• The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease — Recruiting now